Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.

Autor: Marcus M Ilg, Alice R Lapthorn, David J Ralph, Selim Cellek

Publikováno v: PLoS ONE, Vol 17, Iss 12, p e0277646 (2022)

Drug repurposing has been shown to bring safe medications to new patient populations, as recently evidenced by the COVID-19 pandemic. We investigated whether we could use phenotypic screening to repurpose drugs for the treatment of Peyronie's disease

Externí odkaz: https://doaj.org/article/ac660161baea4928928a642471000717

European Society for Sexual Medicine Consensus Statement on the Use of the Cavernous Nerve Injury Rodent Model to Study Postradical Prostatectomy Erectile Dysfunction

Autor: Giovanni Corona, Emmanuel Weyne, Carlo Bettocchi, Marcus M. Ilg, Maarten Albersen, Fabio Castiglione, Asif Muneer, Delphine Behr Roussel, Onur Omer Cakir, Javier Angulo, Yacov Reisman

Publikováno v: Sexual Medicine, Vol 8, Iss 3, Pp 327-337 (2020)
DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
instname
Sexual Medicine
Sexual Medicine, 2020, 8 (3), pp.327-337. ⟨10.1016/j.esxm.2020.06.007⟩

Introduction Rodent animal models are currently the most used in vivo model in translational studies looking into the pathophysiology of erectile dysfunction after nerve-sparing radical prostatectomy. Aim This European Society for Sexual Medicine (ES

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd188add571800d9267700694c2b278
http://www.sciencedirect.com/science/article/pii/S2050116120300830

Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease

Autor: Stephen A. Bustin, M. Mateus, Trinity J. Bivalacqua, Asif Muneer, David Ralph, Michael J. Carpenter, Selim Cellek, Simon J. Stafford, Marcus M. Ilg

Background Myofibroblast transformation is a key step in the pathogenesis of Peyronie's disease (PD). Phosphodiesterase type 5 inhibitors (PDE5is) and selective estrogen receptor modulators (SERMs) can prevent the formation of fibrosis in in vitro an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f26cddc82d7dd55f62c92c1bce7a1610
https://arro.anglia.ac.uk/id/eprint/705818/1/Ilg_2020.pdf

What role do pharmaceuticals play in the treatment of Peyronie’s disease and is there a need for new emerging drugs?

Autor: Maarten Albersen, Marcus M. Ilg, Selim Cellek, Uros Milenkovic

INTRODUCTION Finding novel medical treatment for Peyronie's disease (PD) has suffered from similar limitations and difficulties as other fibrotic diseases.Areas covered: Underlying fibrosis, there is a vastly complex intertwining of several pathways.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53437391a973de7ebb1df0892a243796

Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models

Autor: M. Mateus, Nim Christopher, Marcus M. Ilg, Maarten Albersen, Selim Cellek, Asif Muneer, David Ralph, W. Stebbeds, Uros Milenkovic

Publikováno v: European urology. 75(2)

BACKGROUND: Peyronie's disease (PD) is a fibrotic disorder of the penile tunica albuginea, characterised by the formation of a localised fibrous plaque that can lead to deformity and erectile dysfunction. Nonsurgical therapeutic options for PD are li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c5cfc1374818932cd26a6b7048091d4
https://pubmed.ncbi.nlm.nih.gov/30344087